Vertex, Moderna prepare to take their inhaled mRNA cystic fibrosis drug into the clinic
Vertex and Moderna’s partnership on cystic fibrosis is finally starting to bear fruit.
The two announced Monday morning that the first program from their collaboration will enter the clinic “in the coming weeks” after the FDA cleared its IND. Researchers will test the drug, known as VX-522, in adults with cystic fibrosis in a single dose escalation study. Participants must also have “a CFTR genotype not [be] responsive to CFTR modulator therapy,” Vertex added.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,800+ biopharma pros reading Endpoints daily — and it's free.